Experimental: Cohort A: PD-L1 TPS≥ 1%
Adagrasib 400mg twice daily (BID) x 2 cycles followed by adagrasib 400mg BID in combination with pembrolizumab
Drug: Adagrasib in combination with pembrolizumab
Adagrasib will be administered orally twice daily in a continuous regimen
Biological: Pembrolizumab
Pembrolizumab will be administered as an intravenous infusion once every 3 weeks
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
